What is Palvella Therapeutics's stock issuance proceeds?

Palvella Therapeutics (PVLA) reported stock issuance proceeds of $230M in Q1 2026.

What is the long-term trend for Palvella Therapeutics's stock issuance proceeds?

Over 3 years (2021 to 2025), Palvella Therapeutics's stock issuance proceeds has grown at a -72.9% compound annual growth rate (CAGR), from $38.19M to $763K.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Palvella Therapeutics PVLA Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Viridian Therapeutics, Inc.VRDN

$0-100%

ANI PharmaceuticalsANIP

$2.2M-13.1%

PrecigenPGEN

$0+100%

Arcutis Biotherapeutics, Inc.ARQT

$1.07M—

Kodiak Sciences IncKOD

$922K+644%

LQD

Liquidia CorporationLQDA

$1.75M+38.6%

Other financials

Income statement

See full

Revenue$53.0K-97.3%

Operating income-$14.9M-88.7%

Net income-$15.8M-92.6%

EPS (diluted)-$1.20-62.2%

Balance sheet

See full

Cash & equivalents$206.4M+173%

Total debt$584.0K—

Total equity$232.3M+318%

Total assets$263.8M+232%

Cash flow

See full

Operating cash flow-$10.9M-60.5%

CapEx--100%

Free cash flow-$2.7M+72.0%

Valuation

See full

Market cap$1.7B+468%

Enterprise value$1.5B—

P/S41.6×—

Profitability

See full

Operating margin-183.2%-13.5pp

Net margin71.7%+40.4pp

FCF margin-99.8%-34.2pp

Returns & leverage

See full

Return on equity-34.2%—

Debt / equity0×—

Current ratio28.9×+20.0×

Where this comes from

Reported directly by Palvella Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Palvella Therapeutics's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Palvella Therapeutics's stock issuance proceeds?: Palvella Therapeutics (PVLA) reported stock issuance proceeds of $230M in Q1 2026.
What is the long-term trend for Palvella Therapeutics's stock issuance proceeds?: Over 3 years (2021 to 2025), Palvella Therapeutics's stock issuance proceeds has grown at a -72.9% compound annual growth rate (CAGR), from $38.19M to $763K.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.